Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
Clinical trial NCT02499770 · COMPLETED
Trial details
- NCT number
- NCT02499770
- Sponsor
- G1 Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-26
- Primary completion
- 2017-07-03
- Enrollment
- 122
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.